RxDoctor Payments Data

Valerie Bedard, MD

Internal Medicine · Ponce, PRNPI 1871786970

Payments from drug & device makers

$3,961in general payments, 2019–2025

Across 136 payments — averaging $29.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$673
  • Bayer Puerto Rico Inc.$542
  • AstraZeneca$535
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$386
  • PBG Puerto Rico LLC$383
  • Corcept Therapeutics$247
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$3,65092%
  • Education$3118%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,961 in reported general payments places this provider in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$4,006
Medicare patients
18
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol109$117,141
TrulicityDulaglutide88$96,619
JardianceEmpagliflozin63$92,633
JentaduetoLinagliptin/Metformin Hcl65$66,077
EliquisApixaban72$63,447
TradjentaLinagliptin65$58,173
JanumetSitagliptin Phos/Metformin Hcl64$56,402
XareltoRivaroxaban46$49,766
Trijardy XrEmpaglifloz/Linaglip/Metformin44$49,340
SynthroidLevothyroxine Sodium412$48,048
BrilintaTicagrelor54$46,872
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$42,917
JanuviaSitagliptin Phosphate30$42,451
SynjardyEmpagliflozin/Metformin Hcl27$29,798
LantusInsulin Glargine,hum.Rec.Anlog117$17,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Jentadueto, Tradjenta, Trijardy Xr, Synjardy$107$296,020264 claims
AstraZenecaFarxiga, Brilinta$535$164,013163 claims
Lilly USA, LLCTrulicity, Humalog, Humulin 70-30$87$114,636209 claims
MerckJanumet, Januvia$13$98,85394 claims
Johnson & JohnsonXarelto$673$49,76646 claims
AbbVieSynthroid$120$48,048412 claims
BayerKerendia$117$16,09313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →